Services
Each engagement is scoped to your practice. We combine legal and clinical review so that governance, protocols, and business decisions are risk-aware from the start.
Factual, risk-based analysis of your intended service line against current US federal and state regulation, FDA guidance, and enforcement posture. Written findings identify areas of exposure and defensible positions.
Assessment of financial, operational, insurance, and reputational risks associated with launching a new regenerative service line, including scenario analysis and mitigation planning.
Governance frameworks that clarify medical direction, oversight, escalation, adverse event handling, and documentation — the backbone of a defensible practice.
Practice-specific SOPs, consent frameworks, and treatment protocols developed jointly by clinical and legal leads and tailored to your therapies and patient population.
Structured education for practitioners and staff covering regulatory context, clinical rationale, documentation, and patient communication for regenerative therapies.
Structured due-diligence guidance for peptide, exosome, and stem cell suppliers — helping you ask the right questions and document your reasoning.
[Placeholder] Engagement models, fee structures, and typical timelines can be listed here once finalized.
Advisory Call
Book a scoping call to discuss your practice, the therapies you're considering, and where risk-based advisory work can help.